Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.
Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, Tovar N, Oliver-Cáldes A, Vucinic V, Kharboutli S, Bärmann BN, Ayuk F, Platzbecker U, Stölzel F, Schub N, Schmitz F, Fandrei D, Born P, Khandanpour C, Hanoun C, Hörster K, Teichert M, Jeker B, Hoffmann M, Kröger N, de Larrea CF, Pabst T, Gagelmann N.
Merz M, et al. Among authors: muller f.
Hemasphere. 2025 Jan 16;9(1):e70070. doi: 10.1002/hem3.70070. eCollection 2025 Jan.
Hemasphere. 2025.
PMID: 39822585
Free PMC article.